Patients with diabetes mellitus exhibit hyperglucagonemia, or excess glucagon secretion, which may be the underlying cause of the hyperglycemia of diabetes. Defective alpha cell secretory responses to ...

Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some ...

Veiga-Fernandes and colleagues reported on their findings in Science, in a paper titled “Neuronal-ILC2 interactions regulate pancreatic glucagon and glucose homeostasis.” In their report the ...

MBX Biosciences announced positive Phase 1 clinical trial results for its investigational drug MBX 1416, a long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, which is being developed ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...